Evidence map›Paper›PMID 38379132›Full record

Trial reportJournal of the International AIDS Society2024

My Way: development and preliminary evaluation of a novel delivery system for PrEP and other sexual health needs of young women in Western Kenya.

Jessica E Haberer, Kevin Oware, Lawrence Juma, Bernard Nyerere, Vincent Momanyi, Josephine Odoyo, Lindsey Garrison, Julita Bhagat, Nicholas Musinguzi, Jared M Baeten and 2 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the International AIDS Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Jessica E HabererMassachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-5845-3190
Kevin OwareKenya Medical Research Institute, Kisumu, Kenya.
Lawrence JumaKenya Medical Research Institute, Kisumu, Kenya.
Bernard NyerereKenya Medical Research Institute, Kisumu, Kenya.
Vincent MomanyiKenya Medical Research Institute, Kisumu, Kenya.
Josephine OdoyoKenya Medical Research Institute, Kisumu, Kenya.
Lindsey GarrisonMassachusetts General Hospital, Boston, Massachusetts, USA.
Julita BhagatArk Africa, Nairobi, Kenya.
Nicholas MusinguziGlobal Health Collaborative, Mbarara, Uganda.
Jared M BaetenUniversity of Washington, Seattle, Washington, USA.ORCID 0000-0001-8242-8438
Aaron SieglerEmory University, Atlanta, Georgia, USA.ORCID 0000-0001-5553-7540
Elizabeth A BukusiKenya Medical Research Institute, Kisumu, Kenya.
Kenya Medical Research Institute · KEUniversity of Washington · USEmory University · USHarvard University · USMassachusetts General Hospital · USMbarara University of Science and Technology · UGThe Ark · IE

Funding

PrEP My Way: A Novel PrEP Delivery System to Meet the Needs of Young African WomenR34MH122362 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI HABERER, JESSICA ELIZABETH · 2020 to 2022
$666k
NIMH NIH HHS R34 MH122362NIMH NIH HHS R34MH122362
6 · The paper itself

Abstract

introductionYoung women in sub-Saharan Africa are a priority population for HIV prevention, yet challenges with adherence and persistence to HIV pre-exposure prophylaxis (PrEP) are common. This study involved the development and pilot testing of My Way-a novel delivery system for PrEP and co-packaged sexual health services.

methodsMy Way was developed in Kisumu, Kenya through a user-centred design process (2020). The intervention involves peer-delivery and support for HIV testing and PrEP use, self-collected vaginal swabs for sexually transmitted infection (STI) testing, pregnancy testing, oral contraceptive pills, self-injectable medroxyprogesterone and/or condoms. My Way was assessed among 16- to 24-year-old sexually active women in a randomized controlled trial versus standard of care (SoC; 2021-2022). Use of PrEP and other sexual health services were tracked at 1, 3 and 6 months for feasibility. Acceptability was determined by questionnaire. The effect of the intervention on tenofovir diphosphate (TFV-DP) levels was assessed by chi-square test (primary outcome); other predictors were explored with regression analysis.

resultsAmong 150 women, the median age was 22 years and the median number of sexual partners was 2. Moderate/severe depression was common (60%). In the intervention arm, peers made 88% (198/225) of possible kit deliveries (177 with PrEP) and 49 STIs were diagnosed. In the SoC arm, 24% (55/225) of expected clinic visits occurred (53 with PrEP); no STI testing was performed. TVF-DP was detected in 16 participants at 6 months: 16% (12/75) in the intervention arm versus 5% (4/75) in the SoC arm (p = 0.03). Persistence among those with ongoing HIV prevention needs (i.e. prevention-effective persistence) was 18% (12/67) versus 7% (4/56; p = 0.08). No women acquired HIV. The intervention was significantly associated with detectable TFV-DP (OR 3.5, 1.1-11.4; p = 0.04); moderate/severe depression trended towards an association with TFV-DP (OR 0.2, 0.03-1.6; p = 0.13).

conclusionsMy Way is a promising delivery system for PrEP and other sexual health services among young women in Western Kenya. We found high feasibility and acceptability. PrEP use was modest, but higher with My Way compared to SoC. Long-acting PrEP formulations may overcome important barriers to PrEP use and should be explored in combination with the My Way delivery model.

Indexed as

Anti-HIV AgentsHIV InfectionsOrganophosphatesPre-Exposure ProphylaxisSexual HealthSexually Transmitted DiseasesAdenineAdolescentAdultFemaleHumansKenyaYoung AdultAdenineAnti-HIV AgentsOrganophosphatestenofovir diphosphateadherenceadolescent girls and young womenAfricaHIV prevention trialspoint of carePrEP

Identifiers

PMID38379132
PMCPMC10879470
OpenAlexW4392002475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.